Perspective Therapeutics (CATX) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Perspective Therapeutics (CATX) has outperformed Larimar Therapeutics (LRMR) over the past year, losing 29.1% versus a loss of 41.7%. Over five years, CATX leads with a -60.3% price change compared with -77.3% for LRMR. Perspective Therapeutics is the larger company by market cap ($309.4 million vs $280.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | LRMR |
|---|---|---|
| Share price | $2.71 | $2.70 |
| Market cap | $309.35M | $280.48M |
| 1-day change | +10.16% | -1.82% |
| YTD return | -10.55% | -27.82% |
| 1-year return | -29.11% | -41.74% |
| 5-year return | -60.32% | -77.31% |
| EPS (TTM) | $-1.33 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $6.42 |
| 52-week low | $1.96 | $2.61 |
| Distance from 52-week high | -56.01% | -57.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +353.51% | +433.33% |
| Average volume | 1.67M | 1.31M |
| Shares outstanding | 114.15M | 103.88M |
| Employees | 163 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CATX has outperformed LRMR by 12.6 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
CATX vs LRMR FAQ
Which is bigger, Perspective Therapeutics or Larimar Therapeutics?
Perspective Therapeutics (CATX) is larger, with a market capitalization of $309.35M compared with $280.48M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, CATX or LRMR?
CATX returned -29.11% over the past 12 months, compared with -41.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.